Medroxyprogesterone+acetate

=Medroxyprogesterone Acetate= Liam



General information
2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate ||
 * **IUPAC Name** || [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-
 * **Molar mass** || 386.52 g/mol ||
 * **Formula** || C 24 H 34 O 4 ||
 * **Melting point** || 208°C ||
 * **Boiling point** || 496°C, decomposes ||
 * **Density** || 1.1 g/cm³ ||


 * **Element** || **C** || **H** || **O** ||
 * **Mass composition** || 74.6% || 8.8% || 16.6% ||
 * **Molar composition** || 38.7% || 54.8% || 6.5% ||

History
MPA was independently discovered in 1956 by Syntex and the Upjohn Company. It was first introduced on 18 June 1959 by Upjohn in the United States under the brand name Provera (2.5, 5, and 10 mg tablets) for the treatment of amenorrhea, metrorrhagia, and recurrent miscarriage. An intramuscular formulation, Depo-Provera (400 mg/mL MPA), was also introduced in 1960 in the U.S. for the treatment of endometrial and renal cancer.

Production
Medroxyprogesterone acetate is produced via the esterification of medroxyprogesterone, or via the methylation of hydroxyprogesterone acetate.

Availability
Medroxyprogesterone acetate is generally not available without a prescription. With a prescription it is available in three forms: 1. Oral supplement (pills) 2. Aqueous solution for intramuscular injection 3. Aqueous solution for subcutaneous injection

Uses
Medroxyprogesterone acetate is used as a female contraceptive, as part of hormone replacement therapy (HRT) for menopausal symptoms, as a treatment for endometriosis, and for treatment of abnormal sexuality in males.